Navigation Links
ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
Date:2/9/2010

ential breakthrough for the treatment of certain patients suffering from vitreoretinal pathologic conditions related to vitreomacular adhesion. Vitreomacular adhesion is thought to play a key role in numerous back of the eye conditions such as macular hole formation, and some forms of macular edema. Vitreomacular adhesion is also associated with much poorer prognosis in certain major eye conditions, including diabetic retinopathy and Age-Related Macular Degeneration (AMD).

ThromboGenics is now conducting an extensive Phase III program with microplasmin, referred to as MIVI-TRUST (Microplasmin IntraVitreous Injection - Traction Release without Surgical Treatment), for the non-surgical resolution of focal vitreomacular adhesion. The patient enrollment for the two Phase III trials was completed in 2009 ahead of schedule. The first results from this Phase III program are due in Q2 2010.

For a full discussion of the results from the Phase II trial (MIVI III), please refer to the Ophthalmology article.[1] Further information is also included in the ThromboGenics press release dated 30 June, 2008 (see http://www.thrombogenics.com).

Steve Pakola, MD, Chief Medical Officer of ThromboGenics and co-author of the Ophthalmology paper, commented, "We are very pleased to have had these results with microplasmin published in such a prestigious journal. The Phase II trial data discussed in the paper demonstrate the exciting potential of microplasmin in treating a range of important back of the eye diseases. We very much look forward to announcing the first results from our Phase III program with microplasmin by mid 2010."

About ThromboGe
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics NV - Q3 2009 Business Update
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
4. ThromboGenics NV Announces Business Update and Half Year Results 2009
5. ThromboGenics NV: Business Update
6. ThromboGenics Announces Business Update and 2008 Full Year Results
7. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
8. ThromboGenics N.V.: Business Update
9. ThromboGenics Announces Half Year Results 2008
10. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
11. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grange™ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... G-CON Manufacturing Inc., the standard in design and ... leadership appointment designed to drive the company’s ambitious growth ... Maik Jornitz, Chief Operating Officer of G-Con Manufacturing, has ... the pioneering company through its next phase of market ... and look forward to providing our next generation of ...
(Date:7/29/2014)... July 29, 2014 White papers ... and cloud based eClinical technologies, have been published by ... These follow a long line of white papers by ... including Life Science Leader, Pharmaceutical Online, and OpenHealthNews. , ... a paper by CTO Marc Desgrousilliers, 'The Five ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The Workgroup ... authority on the use of health IT to create ... Health Plan Identifier (HPID) Workgroup has developed an ... Health Plan and Payer?” The HPID Workgroup, a part ... with the Centers for Medicare and Medicaid Services (CMS) ...
Breaking Biology Technology:Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2
... Ind., Jan. 23 Zimmer Holdings, Inc.,(NYSE: ZMH ... announced,today it will be participating in the Wachovia Securities ... 10:15 a.m. Eastern Time., A live webcast of ... at http://investor.zimmer.com . The webcast will,be archived for ...
... QED International Associates, Inc.,administrator for the HealthShares(TM) ... HealthShares(TM) Exchange-Traded Funds, today announced,that effective at the ... Pharmaceuticals Inc. (Nasdaq: REGN ) will replace ... HealthShares(TM) Composite Index. MGI Pharma is being,acquired by ...
... 23 /PRNewswire/ - Dalton Medicinal Chemistry Partners,the ... announces that it,has achieved another targeted milestone ... (Canada) Ltd., Dalton Medicinal Chemistry Partners ... and synthesize novel compounds against an,antiviral target ...
Cached Biology Technology:QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes 2
(Date:7/29/2014)... that brings together two of the major disciplines behind ... insect fossils through stunning photographs and unique illustrations. , ... Jepson, details the incredible preservation and diversity of fossilised ... what these remarkable fossils can tell us about the ... our planet. Like the mosquito in Jurassic Park, many ...
(Date:7/28/2014)... new discovery of two additional coral communities showing signs of ... footprint of the 2010 spill in the Gulf of Mexico. ... Fisher, professor of biology at Penn State University. A paper ... corals in the Gulf of Mexico will be published during ... Edition of the journal Proceedings of the National Academy ...
(Date:7/28/2014)... John Essigmann and colleagues from the University of Washington had ... they could induce the virus to mutate uncontrollably, they could ... strategy that our immune system uses against many viruses. ... to mutate at an enhanced rate, as expected. But it ... clinical trial reported in 2011. In a new study, however, ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4
... have experienced rotator cuff tears are at increased risk of ... the May 2009 issue of The Journal of Bone ... genetic predisposition as a possible cause for rotator cuff disease," ... University of Utah School of Medicine Orthopaedic Center in Salt ...
... of scientists from Canada, Spain and the United States has ... against environmental stresses like drought, freezing and heat. ... signal adverse conditions and help them adapt," says team member ... the University of Toronto. "If we can control these ...
... cleared tens of thousands of square miles of forests to ... popular food ingredient. Ancient peatlands have been drained and lush ... landscape of equatorial Asia now lies vulnerable to fires, which ... the air as well as the land. A team ...
Cached Biology News:Rotator cuff tears: Are they all in the family? 2International team finds key gene that allows plants to survive drought 2NASA study says climate adds fuel to Asian wildfire emissions 2NASA study says climate adds fuel to Asian wildfire emissions 3NASA study says climate adds fuel to Asian wildfire emissions 4
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
SAPK/JNK Antibody...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
Biology Products: